top of page


Crestview Clinical laboratory, located in our Irvine headquarters, is CLIA-certified by the Centers for Medicare and Medicaid Services. We leverage software and automation to test at volumes that other labs can’t match. Our laboratory capacity can processes hundreds of thousands of tests each year and many thousands of COVID-19 Testing per day for Public and Private Health service providers in Southern California. We deliver your COVID-19 RT-PCR Testing Result within 24 to 48 hours after the samples arrived at our lab.

CrestView Lab is offering two options to help meet the testing needs of Public and Private Health service providers in the Southern California.

Lab Experiment


The CrestView Lab 2019 Novel Coronavirus (COVID-19) Test is a real-time reverse transcription polymerase chain reaction (RT-PCR) test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in oropharyngeal, nasopharyngeal, anterior nasal, and mid-turbinate nasal swab specimens from individuals suspected of having the virus that causes COVID-19. Reverse Transcriptase - quantitative Polymerase Chain Reaction (RT-qPCR) is a standard method that is used with most RNA viruses (like HIV, Hepatitis B and C and others). Reverse Transcriptase is an enzyme that ‘reads’ the RNA strand and synthesizes a complementary DNA strand (cDNA). The cDNA can then be detected using a standard qPCR assay.

Testing is limited to the CrestView Lab, Inc. laboratory located in Irvine, California, which is a Clinical Laboratory, certified high-complexity laboratory.

The CrestView Lab 2019 Novel Coronavirus (COVID-19) Test is intended for use by qualified and trained laboratory personnel specifically instructed and trained in the techniques of real-time PCR assays. The CrestView Lab 2019 Novel Coronavirus (COVID-19) Test is only for use under the Food and Drug Administration’s Emergency Use Authorization. Please refer to FDA’s FAQs on Diagnostic Testing for SARS-CoV-2 for additional information.

Note: Results are for the detection of nucleic acid from SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

Pipetting Samples


Results should be available 24-48 hours after receipt of specimens at Crestview Lab's CLIA-certified laboratory. Turnaround time is measured as the average number of hours from when the sample arrived at Crestview Lab's laboratory to when the result is released to the ordering healthcare provider. In some cases, additional time may be necessary.


Mon - Sat : 9:00 am - 7:00 pm
Sun: Closed


877 429 6607

Thanks for submitting!

Widget Didn’t Load
Check your internet and refresh this page.
If that doesn’t work, contact us.
bottom of page